Diazyme Laboratories, Inc.

Home
United States
Poway, CA
Diazyme Laboratories, Inc.

Diazyme is a clinical chemistry reagent manufacturer that develops IVD assays for use on conventional open channel automated chemistry platforms.

03/19/2026

March is National Kidney Month, and at Diazyme Laboratories, we're proud to highlight the importance of renal markers in advancing kidney health!

Through our cutting-edge assays such as Enzymatic Creatinine and Cystatin C, we're dedicated to providing accurate and reliable testing options that empower healthcare professionals to monitor kidney health with precision and confidence.

Our comprehensive portfolio of renal markers enables clinicians to make informed decisions and tailor treatment strategies for patients with kidney-related conditions.

Join Diazyme Laboratories in recognizing National Kidney Month and advocating for kidney health!

Read More about our Renal and Pancreatic Markers Here:
https://bit.ly/4ioAmRa

03/16/2026

Why Monitor Kappa & Lambda Free Light Chains?

Normally, there's a balance between kappa and lambda free light chains in the bloodstream. However, in certain diseases, particularly plasma cell disorders such as multiple myeloma, there can be an imbalance in the production of these free light chains. This imbalance can lead to an excess of one type of light chain over the other, which is known as a kappa-lambda ratio imbalance.

This imbalance can be detected through laboratory tests, such as Diazyme’s Kappa and Lambda serum free light chain assays, which measures the levels of kappa and lambda free light chains in the blood. Monitoring the kappa-lambda ratio is important in the diagnosis and management of plasma cell disorders.

Learn More about these assays and to support healthcare providers in assessing disease progression and response to treatment.
https://bit.ly/4h7z6kn

03/12/2026

Chronic kidney disease (CKD) is a global health challenge, affecting around 850 million people worldwide.

Early detection and monitoring are crucial for managing the disease and improving patient outcomes. At Diazyme Laboratories, we are committed to empowering healthcare professionals with the tools they need to monitor kidney health with precision and confidence.

Our assays, such as Cystatin C and Enzymatic Creatinine, are designed to aid in the early diagnosis and effective management of CKD, offering a more accurate and reliable approach to kidney disease monitoring. With continuous advancements in biomarker research, we strive to provide the most cutting-edge solutions that support better care and improved quality of life for those affected by kidney disease.

Learn more: https://bit.ly/4ioAmRa

03/09/2026

Have you heard about the PLAC® test? It's a groundbreaking blood test that measures Lp-PLA2, a novel marker of vascular inflammation linked to cardiovascular disease.

Accurately assessing patients’ risk for CHD events remains a significant challenge in primary prevention.

The PLAC® Test for Lp-PLA2 Activity (PLAC® Activity) is the only FDA cleared test for Lp-PLA2 activity with a clinically validated cut-point. The test is analytically robust with performance that has been validated on multiple automated chemistry analyzers.

Why is this important? Because by detecting and monitoring this marker, we can better assess cardiovascular risk and tailor interventions for improved patient outcomes.

Learn how the PLAC® Test can enhance your diagnostic methods today! https://bit.ly/43EY9pJ

03/06/2026

🎥 Simplify Sample Collection for Gastro Health Assays!

Accurate sample collection is key to reliable diagnostic testing for gastrointestinal health, and Diazyme is here to make the process easier than ever. We are excited to announce the release of our Extraction Device Demonstration Videos, which guide users through the streamlined process of sample collection for calprotectin, lactoferrin, and pancreatic elastase assays.

These step-by-step videos ensure that your sample collection process is as simple, efficient, and accurate as possible, with consistent results every time. Whether you're testing for inflammation in the gut or digestive enzyme function, Diazyme’s Extraction Device makes it easier to get reliable, reproducible results.

Key Benefits of the Extraction Device:

Minimized Variability: Ensures accurate and consistent sample collection across all tests.

Ease of Use: Simple instructions for both Export (DZ202A-CLDF) and U.S. (DZ202A-ALP) devices.

Enhanced Lab Efficiency: Standardized protocols help improve workflow and reduce errors.

Our Extraction Devices are compatible with all three f***l assays (calprotectin, lactoferrin, and pancreatic elastase), providing a one-stop solution for gastrointestinal diagnostics. Watch the videos now to see how easy it is to gather samples for gastro health testing.

👉 Watch the videos:
For Export Use (DZ202A-CLDF): https://bit.ly/40Lr36w For U.S. Use (DZ202A-ALP): https://bit.ly/40Lr2Q0

03/04/2026

This March, Diazyme Laboratories proudly stands at the forefront of scientific advancement in the fight against myeloma during Myeloma Action Month!

What is Myeloma?
Myeloma is a complex hematological malignancy affecting plasma cells and presents unique challenges in diagnosis and monitoring.

Our Commitment:
Through our state-of-the-art assays, we're driving precision medicine forward, enabling early detection, accurate disease monitoring, and personalized treatment strategies. Diazyme is dedicated to the development of innovative diagnostic solutions for myeloma patients and healthcare providers.

Learn More about Diazyme’s Kappa & Lambda Free Light Chain Assays: https://bit.ly/4h7z6kn

02/27/2026

Diazyme continues to advance cardiovascular diagnostics with solutions that enhance laboratory efficiency and clinical insight. The OxLDL Assay provides fast, automated, cost efficient measurement of oxidized LDL and uncovers risk elements standard lipid tests can miss.

Key Advantages:
• Fast and Automated: Streamlines testing for more efficient laboratory workflows
• Cost-Efficient: Offers a practical alternative for broader cardiovascular testing
• Early Detection: Identifies oxidized LDL and plaque-related risk before traditional markers
• Comprehensive Insight: Measures risk factors not captured by standard cholesterol tests

Discover more about the OxLDL Assay: https://bit.ly/4g1RzhW

02/23/2026

Congenital Heart Defect Awareness Week | The Role of Cardiovascular Biomarkers:

Congenital Heart Defects (CHDs) are the most common birth defects, affecting nearly 1 in 100 newborns. While CHDs are present from birth, monitoring cardiovascular health throughout life is essential for managing potential complications. (https://bit.ly/3Z5aToh)

At Diazyme, our cardiovascular biomarkers help provide critical insights into heart health:
🔹 Homocysteine (HCY): Elevated levels are associated with an increased risk of congenital heart defects and may contribute to cardiovascular disease progression. (https://bit.ly/4q8feCf)
🔹 Lipoprotein(a) [Lp(a)]: A genetically inherited lipoprotein recognized as an independent risk factor for cardiovascular diseases. Elevated Lp(a) levels can adversely affect cardiovascular health in individuals with congenital heart disease (CHD). Monitoring Lp(a) concentrations in these patients is crucial for assessing and managing the risk of additional cardiovascular complications.
(https://bit.ly/4raQTwm)

Raising awareness and improving early detection can make a difference in the lives of those living with CHDs. 💙

Learn more about our Cardiovascular Panel featuring items like OxPL, Apo A, PLAC™ & More: https://bit.ly/3MlnU6y

02/18/2026

Diazyme offers a broad menu of cardiovascular marker assays, including sdLDL, lipoprotein(a), oxLDL, HDL3, and apolipoproteins. These assays support standardized measurement of lipid and lipoprotein markers used in cardiovascular risk assessment.

Explore the full assay menu at https://bit.ly/3C8vYpH

02/17/2026

At Diazyme, we are committed to advancing clinical diagnostics with innovative assays that help clinicians uncover deeper insights into cardiovascular risk factors beyond traditional testing. Our portfolio of cardiovascular biomarkers supports more comprehensive risk assessment, enabling earlier identification of at‑risk patients and more informed clinical decision‑making. These assays reflect our dedication to expanding diagnostic capabilities that can improve patient care and outcomes.

Explore our full cardiovascular biomarker solutions and learn how they can support your laboratory or clinical practice: https://bit.ly/3MlnU6y

02/12/2026

Day 2 & 3 at WHX Labs!

Thank you to everyone who stopped by, asked questions, and shared ideas. We're excited about what's ahead—and we’re proud to continue supporting laboratories with powerful, accessible diagnostic solutions.

Stay Connected with Diazyme after the show: https://www.diazyme.com/contact/

02/12/2026

Discover Diazyme’s sdLDL Assay

Accurately quantify small dense LDL-cholesterol (sdLDL-C) with a homogeneous direct enzymatic method. Diazyme’s sdLDL Assay delivers fast, reliable results using liquid-stable reagents, with no pretreatment or complex workflows required.

• Direct measurement of sdLDL-C
• Results in 10 minutes
• Compatible with most automated clinical chemistry analyzers

Learn more: https://bit.ly/4tjkTIq

For Research Use Only.

Address

12889 Gregg Court
Poway, CA
92064

Website

http://www.diazyme.com/

Alerts

Be the first to know and let us send you an email when Diazyme Laboratories, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your practice to be the top-listed Clinic in Poway?